Background and Aims: Randomized, controlled trials of cardiac resynchronization therapy (CRT) excluded patients with adult congenital heart disease (ACHD). We sought to explore long-term clinical outcomes.
INTRODUCTION
Cardiac resynchronization therapy (CRT) is an established treatment for adult patients with heart failure (HF), impaired left ventricular (LV) function, and a wide QRS complex. 1 Supporting evidence has emerged from numerous randomized, controlled trials and meta-analyses thereof. 2 Consequently, CRT is now widely accepted as a Class I indication (level of evidence A) for selected patients with nonischemic (NICM) or ischemic (ICM) cardiomyopathy.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. It has been shown that CRT in adult congenital heart disease (ACHD) is feasible 3, 4 ; the Pediatric and Congenital Electrophysiol- Moreover, no studies of CRT in the pediatric or ACHD population have involved randomization, and clinical outcome data are also lacking, even from observational studies. 5 In addition, not all observational studies of CRT in ACHD have distinguished between structural ACHD (sACHD) and nonstructural ACHD, such as dilated cardiomyopathy and congenital complete heart block. 5 In the absence of firm evidence in its favor, CRT in ACHD is not permitted in some countries, notably Japan. 6 In the context of the challenges in undertaking randomized, controlled studies in a young, heterogenous population with rare conditions, we sought to compare outcomes of CRT in adults with sACHD, NICM, or ICM.
METHODS
This is a retrospective study of patients with sACHD who had their first CRT device implantation at a tertiary referral center for ACHD 
Endpoints
The primary endpoint was total mortality and the secondary endpoint was cardiac mortality, which included cardiac transplantation or implantation of a ventricular assist device. We also included the ancillary endpoint of unplanned HF hospitalization. Mortality data were collected through medical records and cross-checked with a national mortality database. Clinical outcome data were collected every 6 months by investigators who were blinded to clinical and imaging data. In patients with permanent atrial fibrillation, systemic ventricular and nonsystemic ventricular leads were implanted and a CRT generator was used, plugging the atrial port and programming to a ventricular triggered mode, according to physician's choice. Atrioventricular junction ablation was undertaken according to physicians' decision. Note. Variables are expressed as mean ± standard deviation, unless indicated otherwise. Abbreviations: ACEIs = angiotensin-converting enzyme inhibitors; ARAs = angiotensin receptor antagonists; CABG = coronary artery bypass grafting; CRT-D = cardiac resynchronization therapy-defibrillation; CRT-P = cardiac resynchronization therapy-pacing; ECG = electrocardiogram; ICM = ischemic cardiomyopathy; LBBB = left bundle branch block; MRAs = mineralocorticoid receptor antagonists; NICM = nonischemic cardiomyopathy; NYHA = New York Heart Association; sACHD = structural adult congenital heart disease; SVEF = systemic ventricular ejection function. a Differences between the groups from analysis of variance for continuous variables and from chi-squared tests for categorical variables. b Permanent, persistent, and paroxysmal atrial fibrillation (AF).
Device therapy
Patients underwent a clinical assessment on the day prior to implantation and at 1, 3, and every 6 months following device implantation. 
Statistical analysis

RESULTS
Baseline characteristics
The age distribution in the three study groups is shown in Figure 1 . As shown in Table 1 , patients with sACHD were mostly female (P < .001).
As expected, they were younger (P < .001) and were less likely to have diabetes, hypertension, or a previous coronary artery bypass grafting.
No differences emerged with respect to atrial rhythm, but left bundle branch block (LBBB) was less prevalent in the sACHD group (P < .001).
The sACHD group had a higher proportion of patients on -blockers (P = .002) but the groups were well matched for uptake of loop diuret- LVEF, and treatment with loop diuretics, ACEIs/ARAs, and -blockers also emerged as significant predictors of total mortality (Online Appendix) and these variables were included in multivariate analyses.
Outcomes
Multivariate analyses showed no differences in total mortality, cardiac mortality, or HF hospitalization between sACHD and ICM or NICM (Table 4 ).
DISCUSSION
This is the first study to address long-term outcomes of CRT in patients with ACHD. 5 We found that after CRT, total mortality, cardiac mortality, and HF hospitalization in sACHD were similar to adults with ICM or NICM, after adjustment for potential confounders.
Although CRT is being undertaken in the pediatric and adult population with sACHD, studies in its favor have only focused on surrogate predictors of outcome. In a study of 20 patients, Sakaguchi et al showed that in a mixed population of children and adult patients with a systemic LV or single ventricular physiology, CRT led to a reduction in ventricular volume. 9 In a retrospective study comprising children with CHD (n = 73) or cardiomyopathy (n = 16) (median age 12.8 years; follow-up of 4 months), the SVEF improved after CRT. 4 In a was associated with an increase in SVEF from 36% to 42% (P < .001) and an improvement in functional status was observed in 87% of patients with follow-up data. 10 In this study, more than half of patients with sACHD were upgraded from pacemakers to CRT. This is not unexpected, as both sACHD and operations for sACHD lead to conduction system disturbances.
Although we do not have access to the SVEF prior to pacemaker implantation, the SVEF at the time of upgrade was severely impaired.
This could be due to the natural progression of CHD, but we cannot discount the possibility that subpulmonary ventricular pacing may have contributed to a deterioration in systemic ventricular function.
In this respect, right ventricular (RV) pacing is associated with impairment of LV function and a risk of HF in adult patients with NICM or ICM. [12] [13] [14] [15] In patients with sick sinus syndrome, up to 40% develop HF with RV pacing. 16, 17 In the Dual Chamber and VVI Implantable Defibrillator (DAVID) study 12, 18 and the Mode Selection Trial (MOST), 13 RV pacing was also associated with a higher risk of HF hospitalization.
In patients with CHD, Moak et al showed an improvement in clinical status after upgrading from pacemakers to CRT in six patients aged 11.3 years with NICM. 19 No data are available in patients with sACHD.
Unfortunately, our sample is also too small to explore the effects of upgrading to CRT in sACHD. It would appear, however, that the longterm outcome of CRT in patients with sACHD is comparable to adult patients with NICM, despite the fact that more than half of patients were upgraded from pacemakers. Whether or not pacing the systemic ventricle in patients with sACHD and conventional indications for pacing is preferable to pacing the nonsystemic ventricle remains unexplored.
In this study, patient selection for CRT was driven by the presence of HF symptoms, a wide QRS complex (intrinsic or paced) and impaired SV function, in the background of maximum tolerated medical therapy. Importantly, there will be a selection bias, which was not addressed, insofar as some sACHD patients would not have under-gone CRT because of problems with access to peripheral or coronary sinus veins. Physician preference therefore played a role in patient selection.
Limitations
The small sample size is the main limitation of this study. Given the trends observed herein, larger numbers could show that CRT is better in ACHD after CRT compared to non-ACHD. Clearly, a congenitally abnormal heart is not the same as a structural normal heart with acquired disease. By definition, age is an inescapable covariate of ACHD. Although we have included age in statistical analyses, the biological interaction between age and ACHD cannot be corrected for by statistical means. Caution is therefore appropriate when interpreting the results of these analyses. Unfortunately, follow-up echocardiograms were not systematically collected and therefore, we are unable to comment on the effects of CRT on LV reverse remodeling. Last, we do not have control groups that were not treated with CRT and therefore, we cannot comment on the relative benefit of CRT, but only on the possible effects of the underlying "substrate."
CONCLUSIONS
We found that after CRT, total mortality, cardiac mortality, or HF hospitalization in sACHD was similar to patients with ICM or NICM. Our findings have emerged in the context that observational studies in the sACHD have not addressed long-term outcomes in patients with sACHD and that a randomized controlled trial of CRT in this patient population is unlikely to emerge. 
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